Alnylam Pharmaceuticals, Inc.
ALNY
$292.03
$7.192.52%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 10.50% | -25.75% | 478.84% | -263.14% | 78.21% |
| Total Depreciation and Amortization | 0.35% | -2.15% | -1.01% | -3.20% | 1.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 304.25% | -86.11% | 69.81% | 52.07% | 23.25% |
| Change in Net Operating Assets | -307.00% | 64.26% | -508.69% | 122.86% | -102.27% |
| Cash from Operations | -56.89% | -49.69% | 111.48% | 227.78% | -27.10% |
| Capital Expenditure | 6.26% | -91.83% | 15.05% | -59.34% | 1.36% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 73.27% | -102.70% | 503.85% | -203.54% | 380.12% |
| Cash from Investing | 31.28% | -107.42% | 454.44% | -224.27% | 315.02% |
| Total Debt Issued | -- | -100.11% | -- | -- | -- |
| Total Debt Repaid | -- | 95.42% | -- | -- | -- |
| Issuance of Common Stock | -68.45% | -46.36% | -4.29% | 64.53% | 36.07% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -95.48% | 276.30% | -16.79% | -736.58% | 37.83% |
| Cash from Financing | -65.32% | 110.11% | -934.03% | 16.66% | 48.67% |
| Foreign Exchange rate Adjustments | -23.91% | -514.99% | -103.37% | 95.66% | 181.40% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -67.70% | -55.96% | 302.66% | 74.66% | 140.04% |